Areas of Responsibility. GP responsibilities Consultant responsibilities 1) Reply to the request for shared care as soon as practicable. 2) Prescribe lanreotide/octreotide by brand and at the dose recommended by the specialist. 3) Report to and seek advice from the specialist on any aspect of patient care that is of concern to the GP and may affect treatment. 4) Report any adverse effects to the referring specialist and the MHRA yellow card scheme. 5) Stop treatment on advice of specialist 1) Discuss the possible benefits and side effects of treatment with the patient. 2) Perform baseline tests GH and IGF-1 levels (Acromegaly patients only) 3) Provide results of baseline tests. Discuss potential side effect of gallstone disease with patient. Ultrasonic examination of the abdomen particularly the gall bladder should be undertaken before initiation of treatment and at intervals of 6 – 12 months by specialist. 4) Perform baseline measurements of LFT & blood glucose. 5) Prescribe the lanreotide/octreotide for the first 3 months to exclude any adverse effects. 6) Recommend dose of the drug. 7) Review the patient's condition and monitor response to treatment regularly (3 monthly). 8) Ensure that clear backup arrangements exist for GPs to obtain advice and support. 9) To report any adverse effects to the MHRA yellow card scheme and GP Patient responsibilities • Report any adverse effects to the specialist or GP whilst taking lanreotide/octreotide • Share any concerns in relation to treatment with lanreotide/octreotide • Report to the specialist or GP if they do not have a clear understanding of their treatment
Appears in 3 contracts
Sources: Shared Care Agreement, Shared Care Agreement, Shared Care Agreement